OncoMatch

OncoMatch/Clinical Trials/NCT07023627

A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression

Is NCT07023627 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies INCB123667 for ovarian cancer.

Phase 2RecruitingIncyte CorporationNCT07023627Data as of May 2026

Treatment: INCB123667 — This study will evaluate the safety and efficacy of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer (PROC) With Cyclin E1 Overexpression.

Check if I qualify

Extracted eligibility criteria

Cancer type

Ovarian Cancer

Biomarker criteria

Required: CCNE1 overexpression

Allowed: FOLR1 positive

Prior therapy

Max 4 prior lines
Min 1 prior line

Must have received: platinum-based chemotherapy

platinum-resistant disease: Participants who have only had 1 line of platinum-based therapy must have received at least 4 cycles of a platinum-containing regimen. Participants who have received 2 to 4 lines of platinum-based therapy must have progressed on or within 6 months after the last dose of platinum.

Must have received: bevacizumab (bevacizumab)

Must have received bevacizumab unless there was a contraindication for its use

Must have received: antibody-drug conjugate (mirvetuximab soravtansine)

If the tumor tests positive for FRα, participants must have received mirvetuximab soravtansine unless there is an exception for its use on medical grounds

Cannot have received: platinum-based chemotherapy

Have primary platinum-refractory disease: either did not respond (CR or PR) to first-line platinum-containing therapy or progressed on or within 3 months after the last dose of the first line platinum-containing therapy

Cannot have received: antibody-drug conjugate (mirvetuximab soravtansine)

Exception: medical contraindication

The tumor tests positive for FRα but the participant has not received mirvetuximab soravtansine for any reason other than medical contraindication

Lab requirements

Cardiac function

Clinically significant or uncontrolled cardiac disease within 6 months before the first dose of study drug [excluded]

Clinically significant or uncontrolled cardiac disease within 6 months before the first dose of study drug

Structured fields extracted by AI. May contain errors — verify against the official protocol.

US trial sites

  • Usa Health Mitchell Cancer Institute · Mobile, Alabama
  • Uams Winthrop P Rockefeller Cancer Institute · Little Rock, Arkansas
  • University of California, Los Angeles Medical Center · Los Angeles, California
  • Scripps Healthscripps Mercy Hospital Prebys Cancer Center · San Diego, California
  • Medstar Georgetown University Hospital · Washington D.C., District of Columbia

Showing up to 5 US sites. See all sites on ClinicalTrials.gov →

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify